Transaction DateRecipientSharesTypePriceValue
10th November 2020Fuad El Hibri19,391Open or private sale$88.21$1,710,480.11
10th November 2020Fuad El Hibri19,391Exercise of derivative$26.45$512,891.95
9th November 2020Fuad El Hibri20,000Open or private sale$95.26$1,905,200.00
9th November 2020Fuad El Hibri20,000Exercise of derivative$26.45$529,000.00
6th November 2020Kevin C Tang34,044Open or private purchase$20.63$702,327.72
6th November 2020Kevin C Tang29,682Open or private purchase$22.33$662,799.06
6th November 2020Kevin C Tang2,650Open or private purchase$23.87$63,255.50
6th November 2020Kevin C Tang107,901Open or private purchase$23.48$2,533,515.48
5th November 2020Kevin C Tang8,482Open or private purchase$20.94$177,613.08
5th November 2020Kevin C Tang137,241Open or private purchase$20.78$2,851,867.98
Aptevo Therapeutics
Aptevo Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Aptevo Therapeutics, Inc. was founded on February 22, 2016 and is headquartered in Seattle, WA. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527.

Ticker: APVO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1671584
Employees: 80
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags